Risankizumab versus Deucravacitinib in Adults With Moderate Plaque Psoriasis: 16-Week Results from the Phase 4 IMMpactful Trial - Summary - MDSpire

Risankizumab versus Deucravacitinib in Adults With Moderate Plaque Psoriasis: 16-Week Results from the Phase 4 IMMpactful Trial

  • By

  • Nina Magnolo

  • Jennifer Soung

  • John Frew

  • Antonio Costanzo

  • Hiram Ruiz-Santiago

  • Kilian Eyerich

  • Mar Llamas-Velasco

  • Michael Bukhalo

  • Raja K. Sivamani

  • Angela Moore

  • Tianshuang Wu

  • Jiaheng Xie

  • Manish Patel

  • Doug Ashley

  • Blair Kaplan

  • Vassilis Stakias

  • Ramon Espaillat

  • Richard B. Warren

  • May 17, 2026

Share

Objective:

To compare the safety and efficacy of Risankizumab (RZB) and Deucravacitinib (DEU) in biologic-naïve adults with moderate plaque psoriasis who have not received prior biologic treatment.

Key Findings:
  • Higher proportions of patients treated with RZB achieved PASI 90 and sPGA 0/1 compared to DEU (p<0.05).
  • More patients on RZB achieved PASI 100 and sPGA 0.
  • RZB patients reported better quality of life (DLQI 0/1) and higher treatment satisfaction (TSQM scores) than DEU patients.
Interpretation:

RZB demonstrates superior efficacy in achieving treatment goals and improving quality of life in biologic-naïve adults with moderate plaque psoriasis compared to DEU, highlighting its potential as a preferred treatment option.

Limitations:
  • The study only reports 16-week results; longer-term efficacy and safety data are needed.
  • The open-label design may introduce bias in reporting outcomes, potentially affecting patient-reported results.
Conclusion:

RZB is more effective than DEU for achieving key treatment endpoints in moderate plaque psoriasis, supporting its use as a first-line systemic therapy and providing valuable insights for clinical decision-making.

Original Source(s)

Risankizumab versus Deucravacitinib in Adults With Moderate Plaque Psoriasis: 16-Week Results from the Phase 4 IMMpactful Trial

  • by Nina Magnolo, Jennifer Soung, John Frew, Antonio Costanzo, Hiram Ruiz-Santiago, Kilian Eyerich, Mar Llamas-Velasco, Michael Bukhalo, Raja K. Sivamani, Angela Moore, Tianshuang Wu, Jiaheng Xie, Manish Patel, Doug Ashley, Blair Kaplan, Vassilis Stakias, Ramon Espaillat, Richard B. Warren

  • May 17, 2026

Related Content

First Patient Treated with Proton Therapy at Lynn Cancer Institute

The Eugene M. & Christine E. Lynn Cancer Institute at Boca Raton Regional Hospital, part of Baptist Health, reached an important milestone in the advancement of cancer care with the successful treatment of its first patient utilizing proton therapy, according to physicians at both the Institute and the hospital.

  • by

  • May 15, 2026

  • 5 min
Sigmoidoscopy Reduces CRC Incidence Rates in Men in Norwegian Screening Study

Offering sigmoidoscopy screening led to reduced incidence of colorectal cancer, though more for men vs women, and a reduced rate of colorectal cancer–related mortality in men, according to findings fr...

Local Salvage Therapy for Post-Radiotherapy Local Recurrence of Prostate Cancer

In a systematic review and meta-analysis reported in JAMA Oncology, Miszczyk et al found that local therapies alone are associated with “reasonable efficacy” in select patients with locally radiorecur...

  • May 15, 2026

  • 2 min